Kosan Biosciences has reported positive interim clinical data on KOS-862 and KOS-1584, the company's most advanced epothilone drug candidates.
Epothilones are anticancer agents with a taxane-like mechanism of action that have demonstrated activity in taxane-resistant tumors. KOS-862 has a broad therapeutic index that differentiates it from other compounds in the class and has demonstrated activity in non-small cell lung cancer and breast cancer. KOS-1584 is a second-generation compound with increased potency, favorable tissue distribution, and ease of formulation. Kosan is developing its epothilone compounds in collaboration with Roche.